ABSTRACT
BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that results from various genetic and environmental factors, and type 2 diabetes mellitus (T2DM) combined with coronary heart disease (CHD) is one of the most common chronic complications in diabetes. AIM: To explore the correlation between the polymorphism of angiotensin-converting enzyme 2 (ACE2) and T2DM combined with CHD. PATIENTS AND METHODS: A total of 120 patients with T2DM and 93 patients with T2DM and CHD were selected to participate in this study. And polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) was used to analyze the polymorphism of G8790A in ACE2 gene. Meanwhile, the clinical, biochemical and echocardiographic data were also analyzed. RESULTS: There was no significant difference between T2DM group and T2DM combined with CHD group in genotype and allele frequencies (p > 0.05). And for different genotypes, both groups had no significant difference in the age, BMI, blood lipid, fasting blood glucose, EF ratio, E/A ration, LVPWTd and LVEDd (p > 0.05). But for male patients in T2DM combined with CHD group, the IVSTd, LVPWTd and urine protein level of allele G were significantly higher than that of allele A with p values less than 0.01, 0.05 and 0.05, respectively. CONCLUSIONS: Genetic polymorphism of G8790A in ACE2 gene plays an important role on the pathogenesis of male patients with T2DM and CHD by changing the levels of IVSTd, LVPWTd and urine protein. Therefore, our results reveal the role of ACE2 polymorphism in the pathogenesis of T2DM with CHD and identify several potential biomarkers for this disease.
Subject(s)
Coronary Disease/genetics , Diabetes Mellitus, Type 2/genetics , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Adult , Aged , Angiotensin-Converting Enzyme 2 , Case-Control Studies , Echocardiography , Female , Genotype , Humans , Male , Middle AgedABSTRACT
Ofloxacin, a new quinolone antibacterial agent, is active in vitro against gonococcal and nongonococcal urogenital pathogens. Chlamydia trachomatis infection is the most common cause of nongonococcal urethritis. In a multicenter study in seven Asian countries, 105 mal patients with chlamydial urethritis and 46 male patients with nongonococcal and nonchlamydial urethritis were treated with oral ofloxacin at a dosage of 200 mg twice daily for 5 to 10 days. The evaluation performed at day 5 and/or day 10 after treatment revealed good results in 58.2% and 96.8% of the chlamydial urethritis group, and 73.1% and 79.4% of the nongonococcal, nonchlamydial urethritis group, respectively. No severe side effects were observed. Ten-day treatment with ofloxacin showed good clinical efficacy on nongonococcal urethritis.
